跳至主要内容
临床试验/CTRI/2018/07/015039
CTRI/2018/07/015039尚未招募未知

To evaluate the safety and feasibility of HLA-mismatched stem cell microtransplantation in relapsed and refractory acute myeloid leukemia (AML)patients who do not have matched sibling donor : A single arm prospective,interventional, pilot study â??

DEPARTMENT OF MEDICAL ONCOLOGY AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 18-65 years
  • 2. No 10/10 matched sibling and matched unrelated donor available
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and estimated survival of at least 3 months
  • 4. Patients must be able to understand and agree to sign an Institutional Review Board (IRB)-approved informed consent form
  • 5)Patient has at least one medically fit first- or second-degree family member expected to be human leukocyte antigen (HLA) mismatched at 2-9/10 loci; in addition, the prospective donor is willing to voluntarily donate hematopoietic stem cells and sign consent forms

排除标准

  • 1. Acute promyelocytic leukemia
  • 2. Therapy related AML/ MDS-AML
  • 3. Chronic myeloid leukemia in accelerated phase and blastic phase
  • 4. Previous allogeneic or autologous HSCT or solid organ transplantation

研究者

发起方
DEPARTMENT OF MEDICAL ONCOLOGY AIIMS

相似试验